HCA Healthcare (HCA) Stock After Recent Slide And DCF Upside Potential

Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE.

If you are wondering whether HCA Healthcare stock offers solid value at today's price, the key is to separate short term noise from what the underlying business may be worth. The shares last closed at US$392.33, with returns of 4.1% over the past week and 3.6% over the past month, while the year to date move shows a decline of 16.6% and the return over the last year is 3.1%. These moves sit against a longer backdrop where HCA Healthcare has returned 35.0% over three years and 90.4% over five years. This helps frame how investors have been willing to price the stock over different time horizons. This context matters for anyone trying to judge whether recent price action reflects changing expectations, shifting risk perceptions, or simply normal volatility. On Simply Wall St's valuation checks, HCA Healthcare currently scores 6 out of 6. This sets the stage for a closer look at how traditional valuation tools like P/E, multiples, and discounted cash flow line up, and hints at an even more complete way to think about value that will be covered at the end of this article.

Find out why HCA Healthcare's 3.1% return over the last year is lagging behind its peers.

Approach 1: HCA Healthcare Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow, or DCF, model estimates what HCA Healthcare stock could be worth today by projecting future cash flows and discounting them back to a present value using a required rate of return.

For HCA Healthcare, the model uses last twelve months Free Cash Flow of about $7.8b and a 2 Stage Free Cash Flow to Equity approach. Analysts provide explicit forecasts for several years, and beyond that Simply Wall St extrapolates additional cash flows. By 2030, projected Free Cash Flow is $7.97b, with intermediate years between 2026 and 2035 ranging from about $7.1b to $9.4b before discounting.

When all those projected cash flows are discounted back and aggregated, the DCF model suggests an intrinsic value of about $773.22 per share. Compared with the recent share price of $392.33, this implies the stock screens as roughly 49.3% undervalued on this model.

Result: UNDERVALUED

Our Discounted Cash Flow (DCF) analysis suggests HCA Healthcare is undervalued by 49.3%. Track this in your watchlist or portfolio, or discover 42 more high quality undervalued stocks.HCA Discounted Cash Flow as at Jun 2026

Head to the Valuation section of our Company Report for more details on how we arrive at this Fair Value for HCA Healthcare.

Story Continues

Approach 2: HCA Healthcare Price vs Earnings

For profitable companies like HCA Healthcare, the P/E ratio is a useful shorthand for how much investors are paying for each dollar of current earnings. It links directly to what the business is earning today, which many investors find easier to relate to than long range cash flow forecasts.

What counts as a "normal" or "fair" P/E ratio often reflects how the market views a company's growth prospects and risk. Higher expected growth or perceived resilience can support a higher multiple, while more uncertainty or weaker profitability can pull it down.

HCA Healthcare currently trades on a P/E of 12.81x. That sits below the Healthcare industry average P/E of about 24.78x and below a peer group average of about 14.37x. Simply Wall St's Fair Ratio for HCA Healthcare is 24.60x, which represents the P/E level suggested by its model after accounting for factors such as earnings growth, profit margins, industry, market value and risk characteristics.

This Fair Ratio can be more useful than simple peer or industry comparisons because it aims to tailor the benchmark to the specific company rather than relying on broad group averages. Comparing the current P/E of 12.81x with the Fair Ratio of 24.60x indicates that, on this metric, the stock screens as undervalued.

Result: UNDERVALUEDNYSE:HCA P/E Ratio as at Jun 2026

P/E ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 20 top founder-led companies.

Upgrade Your Decision Making: Choose your HCA Healthcare Narrative

Earlier this article mentioned that there is an even better way to understand valuation. This is where Narratives come in: a simple way for you to write the story you believe about HCA Healthcare, connect that story to assumptions about future revenue, earnings and margins, and translate it into a Fair Value you can compare with today's price.

A Narrative on Simply Wall St is essentially your HCA Healthcare thesis written in numbers and words together. It links your view of the business to a forecast and then to a Fair Value estimate that updates automatically when new information such as earnings, news or guidance is added to the platform's Community page.

For example, one HCA Healthcare Narrative on the cautious side sets a Fair Value around US$396.00, using assumptions like 4.5% annual revenue growth, margins easing from 8.9% to 8.3% and a P/E of 12.9x in 2029. A more optimistic Narrative sits closer to US$627.69, with 5.9% revenue growth, margins at 8.7% and an 18.8x P/E. By comparing each Fair Value with the current share price, investors can decide whether those stories suggest the stock looks expensive, cheap or roughly in line with their expectations.

Do you think there's more to the story for HCA Healthcare? Head over to our Community to see what others are saying!NYSE:HCA 1-Year Stock Price Chart

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include HCA.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email [email protected]

View Comments